A Phase 2a Study of DP2-antagonist GB001 for Asthma.
GB001, a DP2 antagonist, may inhibit recruitment and activation of inflammatory cells in patients with asthma, consequently reducing airway inflammation. Explore the efficacy and safety of GB001 in adults with mild-moderate asthma. During a 4-week run-in period, adult asthma patients (N=158) received medium-dose ICS and placebo and were then randomized to treatment once-daily with GB001 5 mg, 20 mg, or placebo for 16 weeks or until asthma worsening/exacerbation. Patients were tapered to and then discontinued from low-dose ICS at randomization and 4 weeks post-randomization, respectively. Primary endpoint was change in morning peak expiratory flow (AM PEF); secondary endpoints included measures of asthma control. Safety was also assessed. Baseline characteristics were similar among GB001 5 mg, 20 mg and placebo groups. Changes in AM PEF in 5 mg and 20 mg groups versus placebo showed mean differences (95% CI) of 15.2 (3.1, 27.4) L/min, p=0.02 and 13.7 (1.5, 25.8) L/min, p=0.03, respectively. The changes in FEV1 of 55 ml and 32 ml, respectively were not significant. There was a significant difference between GB001 20mg and placebo for the secondary endpoints of time to asthma worsening/exacerbation (hazard ratio 0.29), ACQ-5 (-0.60 points), the percent of days without asthma symptoms (26%) and the percent of rescue-free days (22%). Patients with baseline eosinophils ≥300/μL had larger differences between GB001 20mg and placebo for changes in AM PEF. Similar effects were seen in a post-hoc analysis for time to worsening/exacerbations and ACQ-5. The most common non-serious adverse event in the GB001 groups compared to the placebo group was nasopharyngitis. GB001 was well tolerated and while not associated with clinically meaningful changes in lung function, improvements in asthma worsening/exacerbations and markers of asthma control were demonstrated. In addition, greater treatment effects were observed in patients with high baseline blood eosinophils. Further studies are needed to confirm these findings in the context of standard of care treatment.